Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Biotech Roundup: Index Creation, Winner!, Technobabble, Humor


Happy Friday the 13th!


Stories on Index Creation

We're in the final stages of creating the BSR Biotech Index™. It will be coming to a computer screen near you soon. My firm has screened over 800 companies and discovered there are about 250 we consider "development stage biotech." I'm looking forward to being able to produce a benchmark that finally suits biotech investors – as opposed to those interested in investing in biopharma and pharma companies.

The process has been a real grind, but it has had its moments. For example, did you know:

  • There is a company creating a daily-use rub-on crème for the treatment of kidney cancer. I find this exceptionally odd as it would be onerous for a patient to have to open themselves up to rub a crème on their kidneys every day.

  • Chemed (CHE) offers hospice care services and… Roto-Rooter. The mind simply whirls with the punny potential in that pairing.

  • Many services classify funeral home companies as "healthcare." If that's true, are casket makers medical device manufacturers in disguise?

And speaking of medical devices, what a wild and slightly disturbing ride it is to visit their web sites. I often had to resist describing their product offerings as "Devices – Medieval Torture"

Winner! (So Far)

The Anormed (ANOR) bidding war seems to have been won by Genzyme (GENZ), but Millenium Pharma (MLNM) gets the right of last bid. Analysis is that Genzyme smartly bid just enough to force Millennium to go to a cash and stock offer to beat their bid. Given the loose purses of the bond market, though, I expect that Millennium could come up with the cash if it wanted to.

Bidding wars are fun when you own the target, but I'm hoping I never have to be an owner of one of the bidders. Acquisitions so rarely work out as planned anyway, and overlaying that with a bidding process that drives the price to exorbitant levels just makes it all that much worse.


The founder of Novell (NOVL) died this week. For geeks of a certain age, Novell was the company that introduced peer-to-peer networking to the masses, forever altering the way we work. I was never a fan of their networking technology (too much constant babysitting) as I was a LANtastic fan, but his passing still deserves some mention and a thank you.

Microsoft's (MSFT) Vista will ship soon. My firm is pushing up our planned hardware purchases to avoid the release, preferring to stick with the devil we know (XP). I wonder how many others are thinking of doing the same.

I installed Netgear's (NTGR) SC-101 attached storage unit last weekend on the office network. It's a toaster-looking gizmo that you slap a couple of hard drives in for network-accessible storage. We use it as a backup for everyone's important files. All went well until I realized the core client software necessary for each machine to communicate to the toaster (a) prevents USB ports from working properly, and (b) Prevents XP from shutting down properly. If any Netgear folks are listening, please check out ticket # 3888430.

Friday Humor

I really tried to cleverly work this and this into the commentary. I failed, but that's no reason for you to miss out on the fun.

< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos